Use of home parenteral nutrition in severely neurologically impaired children.


Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
04 2022
Historique:
received: 13 02 2021
accepted: 04 09 2021
pubmed: 24 9 2021
medline: 29 4 2022
entrez: 23 9 2021
Statut: ppublish

Résumé

To review the outcome of children with severe neurological impairment (NI) and intestinal failure (IF) referred to our specialist multidisciplinary IF rehabilitation service and to discuss implications. Case report series, descriptive analysis. IF rehabilitation programme at a tertiary children's hospital in the UK. Children with severe NI referred to our IF rehabilitation programme from 2009 to 2019. Demographic and social data, diagnosis, clinical condition, use of home parenteral nutrition (HPN), complications, ethics review outcome and advance care plans. Six patients with severe NI were referred to our IF rehabilitation service. Consent for publication was obtained from five families. After thorough medical review and clinical ethics committee assessment, three children started HPN, one had intravenous fluids in addition to enteral feed as tolerated and one intravenous fluids only. The HPN children survived 3-7.08 years (median 4.42 years) on treatment. Objective gastrointestinal signs, for example, bleeding improved without excessive HPN-related complications. Symptomatic improvement was less clear. Analgesia was reduced in three of the five children. All cases had detailed symptom management and advance care plans regularly updated. HPN can play a role in relieving gastrointestinal signs/symptoms in children with severe NI and IF. HPN can be conceptualised as part of good palliative care if judged to be in the child's best interests. However, given its risks and that HPN has the potential to become inappropriately life-sustaining, a thorough ethics review and evaluation should be performed before it is initiated, withheld or withdrawn in children with severe NI.

Identifiants

pubmed: 34551897
pii: archdischild-2021-321850
doi: 10.1136/archdischild-2021-321850
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

365-370

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Francisco Ribeiro-Mourão (F)

Pediatrics Department, Alto Minho Local Health Unit EPE, Viana do Castelo, Portugal.
Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK.

Sophie Bertaud (S)

Louis Dundas Centre for Children's Palliative Care, Great Ormond Street Hospital for Children, London, UK.

Joe Brierley (J)

Paediatric Bioethics Centre, Great Ormond Street Hospital for Children, London, UK.

Renee McCulloch (R)

Louis Dundas Centre for Children's Palliative Care, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Jutta Köglmeier (J)

Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK.

Susan M Hill (SM)

Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK susan.hill@gosh.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH